Literature DB >> 27448835

High prevalence of extensively drug-resistant and metallo beta-lactamase-producing clinical Acinetobacter baumannii in Iran.

Hossein Maspi1, Hamideh Mahmoodzadeh Hosseini2, Mohsen Amin3, Abbas Ali Imani Fooladi4.   

Abstract

Acinetobacter species particularly Acinetobacter baumannii (A. baumannii) have been widely reported as broad-spectrum antibiotic resistant pathogens. Expression of various types of metallo beta-lactamases (MBL), classified as Ambler class B, has been associated with carbapenem resistance. Here, we attempted to assess the frequency of extensively drug-resistant (XDR) and MBL-producing A. baumannii among clinical isolates. 86 clinical A. baumannii strains were collected from 2014 to 2015 and their susceptibility to meropenem (10 μg), imipenem (10 μg), azteronem (30 μg), pipracillin (100 μg) tazobactam (110 μg), tobramycin (10 μg), fosfomycin (200 μg), rifampicin (5 μg), colistin (10 μg), tigecycline (15 μg), sulbactam/ampicillin (10 μg + 10 μg) and polymixin B (300 U) was evaluated using disk diffusion method. The MBL-producing isolates were screened using combined disc diffusion method. Furthermore, the presence of blaVIM, blaIMP, blaSPM, blaGIM, blaSIM and blaNDM was detected by PCR. 34.9% of isolates were recovered from bronchoalveolar lavage (BAL). 81 (94.2%) and 62 (71.2%) isolates were multidrug resistance (MDR) and XDR, respectively. 44 (51.2%) and 65 (75.6%) isolates were MBL-producing strains with resistance to imipenem and meropenem, respectively. 2 (2.3%), 13 (15.1%), 2 (2.3%), 4 (4.7%) and 2 (2.3%) isolates carried blaVIM, blaIMP, blaSPM, blaGIM and blaSIM genes, respectively. Our data showed that the rate of XDR and MBL A. baumannii is on the rise.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Acinetobacter baumannii; MBL; MDR; XDR

Mesh:

Substances:

Year:  2016        PMID: 27448835     DOI: 10.1016/j.micpath.2016.07.011

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  7 in total

1.  Genotyping and molecular characterization of clinical Acinetobacter baumannii isolates from a single hospital in Southwestern Iran.

Authors:  Ahmad Farajzadeh Sheikh; Mohammad Savari; Effat Abbasi Montazeri; Saeed Khoshnood
Journal:  Pathog Glob Health       Date:  2020-06-19       Impact factor: 2.894

2.  Investigation of Class I, II, and III Integrons Among Acinetobacter Baumannii Isolates from Hospitalized Patients in Isfahan, Iran.

Authors:  Mehrdad Halaji; Aliakbar Rezaei; Mehrdad Zalipoor; Jamshid Faghri
Journal:  Oman Med J       Date:  2018-01

Review 3.  The threat of carbapenem-resistant gram-negative bacteria in a Middle East region.

Authors:  Effat Davoudi-Monfared; Hossein Khalili
Journal:  Infect Drug Resist       Date:  2018-10-17       Impact factor: 4.003

Review 4.  Insight into Acinetobacter baumannii: pathogenesis, global resistance, mechanisms of resistance, treatment options, and alternative modalities.

Authors:  Muhammad Asif; Iqbal Ahmad Alvi; Shafiq Ur Rehman
Journal:  Infect Drug Resist       Date:  2018-08-21       Impact factor: 4.003

5.  Carbapenem resistance in Acinetobacter baumannii clinical isolates from northwest Iran: high prevalence of OXA genes in sync.

Authors:  Abolfazl Vahhabi; Alka Hasani; Mohammad Ahangarzadeh Rezaee; Behzad Baradaran; Akbar Hasani; Hossein Samadi Kafil; Elgar Soltani
Journal:  Iran J Microbiol       Date:  2021-06

6.  AdeR-AdeS mutations & overexpression of the AdeABC efflux system in ciprofloxacin-resistant Acinetobacter baumannii clinical isolates.

Authors:  Abdolaziz Rastegar Lari; Abdollah Ardebili; Ali Hashemi
Journal:  Indian J Med Res       Date:  2018-04       Impact factor: 2.375

Review 7.  Understanding the Epidemiology of Multi-Drug Resistant Gram-Negative Bacilli in the Middle East Using a One Health Approach.

Authors:  Iman Dandachi; Amer Chaddad; Jason Hanna; Jessika Matta; Ziad Daoud
Journal:  Front Microbiol       Date:  2019-08-23       Impact factor: 5.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.